Best birth control for gastric sleeve patients is an important consideration both before and after surgery. Gastric sleeve (sleeve gastrectomy) is a restrictive bariatric procedure that removes most of the stomach but leaves the small intestine intact — a key distinction that influences which contraceptive methods are safe and effective. Fertility often improves significantly after surgery, making reliable contraception essential during the post-operative period. This article outlines UK-recommended options, explains how surgery affects hormonal contraception, and covers pregnancy planning guidance from the FSRH, NICE, UKMEC, and RCOG.

How Gastric Sleeve Surgery Affects Contraceptive Absorption

Gastric sleeve surgery does not alter the small intestine, so oral contraceptive absorption is generally acceptable post-operatively; however, early post-operative vomiting or diarrhoea may temporarily reduce reliability, and standard FSRH missed-pill guidance applies.

Not sure if this is normal? Chat with one of our pharmacists →

Gastric sleeve surgery (sleeve gastrectomy) removes approximately 75–80% of the stomach, creating a narrow, tube-shaped pouch. Crucially, this is a restrictive procedure — it does not alter the small intestine, where most drug absorption takes place. This distinguishes it from malabsorptive procedures such as Roux-en-Y gastric bypass (RYGB), which bypass a significant portion of the small bowel and pose a much greater risk of reduced oral medication absorption.

Because the small intestine remains intact after sleeve gastrectomy, the Faculty of Sexual and Reproductive Healthcare (FSRH) and the UK Medical Eligibility Criteria (UKMEC) generally consider oral contraceptive methods to be acceptable after restrictive bariatric procedures. The evidence for clinically significant impairment of oral contraceptive absorption specifically after sleeve gastrectomy is limited. That said, accelerated gastric emptying in the early post-operative period may affect how quickly tablets pass into the small intestine, and persistent vomiting or diarrhoea — which can occur in the weeks following surgery — may reduce the reliability of oral contraceptives in the same way as for any patient experiencing gastrointestinal upset. Standard FSRH missed-pill and vomiting/diarrhoea guidance applies in these circumstances.

It is also worth noting that significant weight loss can influence hormone metabolism. Body fat plays a role in oestrogen storage and distribution, so as fat mass decreases rapidly in the months following surgery, hormonal fluctuations may occur. These physiological changes mean that contraceptive choices made before surgery should be reviewed as part of post-operative care — not because oral methods are necessarily unreliable after sleeve gastrectomy, but because individual circumstances, risk factors, and reproductive goals may have changed.

Patients who have undergone or are planning a malabsorptive procedure (e.g., RYGB or biliopancreatic diversion) should be aware that oral hormonal contraceptives are generally not recommended after those operations, due to the risk of substantially reduced absorption. This article focuses primarily on sleeve gastrectomy.

Which Contraceptive Methods Are Recommended After Bariatric Surgery

LARCs are the recommended first-line contraceptive methods after bariatric surgery, as they bypass the gastrointestinal tract entirely; oral contraceptives remain generally acceptable after restrictive procedures but are not recommended after malabsorptive surgery.

Current guidance from the FSRH, UKMEC, and NICE (NG216) supports a personalised approach to contraceptive counselling after bariatric surgery, taking into account the type of procedure, individual risk factors, and reproductive goals.

For sleeve gastrectomy (a restrictive procedure), oral contraceptive methods are generally considered acceptable by UKMEC, provided there are no other contraindications. However, long-acting reversible contraceptives (LARCs) remain the most effective options for all women, including those who have had bariatric surgery, because they bypass the gastrointestinal tract entirely and are unaffected by any changes in gastric function.

Recommended options after gastric sleeve surgery include:

• Long-acting reversible contraceptives (LARCs): Considered the gold standard by NICE and the FSRH. Includes the intrauterine system (IUS), copper intrauterine device (IUD), progestogen-only implant, and progestogen-only injectable. None are affected by gastrointestinal changes.

• Progestogen-only injectable (e.g., Depo-Provera): Administered intramuscularly every 12 weeks; unaffected by gut changes, though see notes on bone mineral density below.

• Non-oral combined hormonal contraception (CHC): The contraceptive patch (e.g., Evra) and vaginal ring (e.g., NuvaRing) bypass the gastrointestinal tract and may be suitable alternatives to the pill for those who prefer a combined hormonal method, subject to individual VTE and oestrogen-related risk assessment.

• Oral contraceptives: Generally acceptable after restrictive procedures (sleeve gastrectomy) per UKMEC, but not recommended after malabsorptive procedures. Individual risk factors (e.g., VTE history, BMI, mobility, migraine with aura) must be assessed.

• Barrier methods: Condoms (male or female) remain effective when used correctly and consistently, though they carry a higher typical-use failure rate and are best used alongside another method.

A healthcare professional should assess each patient's full medical history using the UKMEC framework before recommending any method. NICE NG216 supports a personalised, informed discussion.

Combined Hormonal Contraception and Oral Contraceptives: Considerations After Gastric Sleeve

Combined hormonal contraception must be stopped at least four weeks before bariatric surgery due to VTE risk and restarted only after full mobilisation and clinical review; oral contraceptives are generally acceptable after sleeve gastrectomy per UKMEC.

The combined oral contraceptive pill (COCP) contains both oestrogen and progestogen and is one of the most widely used contraceptive methods in the UK. Following gastric sleeve surgery, its use requires consideration of two distinct issues: perioperative VTE risk and individual suitability.

Perioperative management of combined hormonal contraception (CHC)

Bariatric surgery is classified as major surgery and carries a temporarily elevated risk of venous thromboembolism (VTE). Oestrogen-containing contraceptives independently increase VTE risk. In line with FSRH CHC guidance and BNF/NICE CKS recommendations, CHC (including the pill, patch, and vaginal ring) should be stopped at least four weeks before major elective surgery. Restarting CHC should be considered no sooner than two weeks after full mobilisation, with an individualised assessment of ongoing VTE risk factors such as BMI, immobility, thrombophilia, age, and smoking status. Patients should not simply restart CHC at a fixed time point without clinical review.

Absorption after sleeve gastrectomy

As noted above, UKMEC considers oral contraceptives generally acceptable after restrictive procedures such as sleeve gastrectomy, as the small intestine remains intact. However, if persistent vomiting or diarrhoea occurs post-operatively, standard FSRH missed-pill guidance applies — additional contraceptive precautions (e.g., condoms) should be used during and for seven days after the episode (two days for the progestogen-only pill, depending on formulation).

The progestogen-only pill (POP)

The POP does not carry the same VTE risk as the COCP and is not subject to the same perioperative restrictions. It is generally acceptable after sleeve gastrectomy per UKMEC. However, it requires strict daily timing adherence, and the same vomiting/diarrhoea precautions apply. Non-oral alternatives are often more convenient and reliable for this patient group.

Non-oral CHC options

The contraceptive patch and vaginal ring deliver oestrogen and progestogen without relying on gastrointestinal absorption. They may be suitable for women who prefer combined hormonal contraception after sleeve gastrectomy, but the same oestrogen-related contraindications apply — including migraine with aura, personal or family history of VTE, and high cardiovascular risk. These should be assessed using the UKMEC framework.

Long-Acting Reversible Contraception (LARC) Options to Consider

LARCs — including the IUS, copper IUD, progestogen-only implant, and injectable — are the most effective contraceptive options after gastric sleeve surgery, as none rely on gastrointestinal absorption.

Long-acting reversible contraception (LARC) methods are recommended by NICE (NG216) and the FSRH as the most effective forms of contraception available. Because they are not taken orally, their efficacy is entirely unaffected by changes in gastrointestinal function, making them particularly well suited to women who have had bariatric surgery of any type.

The main LARC options available on the NHS include:

• Levonorgestrel intrauterine system (IUS) — e.g., Mirena (52 mg, licensed up to 8 years for contraception), Kyleena (19.5 mg, 5 years), Jaydess (13.5 mg, 3 years): A small T-shaped device inserted into the uterus that releases a low dose of progestogen locally. Highly effective (less than 1% typical-use failure rate) and does not rely on systemic absorption.

• Copper intrauterine device (IUD): A hormone-free option effective for up to 10 years. Also functions as emergency contraception if inserted within five days of unprotected sex, or up to five days after the earliest estimated date of ovulation. Typical-use failure rate is less than 1%.

• Progestogen-only implant (Nexplanon): A small flexible rod inserted under the skin of the upper arm, releasing etonogestrel continuously for up to three years. One of the most effective contraceptive methods available, with a typical-use failure rate of less than 1%.

• Progestogen-only injectable (Depo-Provera / Sayana Press): Given every 12 weeks by intramuscular or subcutaneous injection; unaffected by gut changes. Typical-use failure rate is approximately 4% (higher than IUD, IUS, or implant). Important considerations for post-bariatric patients: DMPA is associated with a reduction in bone mineral density (BMD) with prolonged use, which may be of particular relevance after bariatric surgery, where calcium and vitamin D deficiency are common. Weight gain has also been reported with DMPA use. These factors should be discussed with patients, and alternatives considered if there is a significant risk of osteoporosis or ongoing micronutrient deficiency. Fertility may also take longer to return after stopping DMPA compared with other LARC methods.

All LARC methods can be discussed and fitted through NHS GP surgeries or sexual health clinics. They are reversible, cost-effective, and particularly well suited to the post-bariatric surgery population. If you experience any suspected side effects from a contraceptive medicine or device, you can report this via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or the Yellow Card app.

Emergency Contraception After Gastric Sleeve Surgery

The copper IUD is the most effective and preferred emergency contraceptive after gastric sleeve surgery; oral options such as levonorgestrel are generally acceptable after restrictive procedures, but the IUD is recommended regardless of body weight.

Emergency contraception (EC) may be needed if unprotected sex has occurred or a contraceptive method has failed. After bariatric surgery, the choice of EC method requires careful consideration.

Copper IUD: This is the most effective form of EC and is recommended as the first-line option for most women, including those who have had bariatric surgery. It can be inserted up to five days after unprotected sex, or up to five days after the earliest estimated date of ovulation, and can then be retained as ongoing contraception. It is unaffected by gastrointestinal changes.

Oral emergency contraception:

• Levonorgestrel (e.g., Levonelle): A progestogen-only tablet taken as a single dose. After sleeve gastrectomy (a restrictive procedure), absorption is generally considered acceptable, as the small intestine is intact. However, if vomiting occurs within two to three hours of taking the tablet, a replacement dose should be sought.

• Ulipristal acetate (ellaOne): A selective progesterone receptor modulator taken as a single dose, effective up to 120 hours (five days) after unprotected sex. There is limited specific evidence on its absorption after bariatric surgery. After malabsorptive procedures, oral EC efficacy may be reduced; the copper IUD is strongly preferred in those cases.

• Both oral EC options may be less effective in women with a higher body weight. Current FSRH guidance advises that the copper IUD is the most reliable EC option regardless of weight.

Emergency contraception is available from NHS sexual health clinics, most pharmacies (without prescription for levonorgestrel), GP surgeries, and some A&E departments. If you are unsure which option is most appropriate for you, contact NHS 111 or a sexual health clinic for urgent advice. Use the NHS sexual health clinic finder at nhs.uk/service-search/sexual-health to locate your nearest service.

Pregnancy Planning and Timing After Gastric Sleeve Surgery

Women should avoid pregnancy for at least 12–18 months after gastric sleeve surgery, or until weight has stabilised, due to risks of nutritional deficiency and rapid weight loss affecting foetal development.

One of the most important aspects of post-operative care for women of reproductive age following gastric sleeve surgery is understanding the recommended waiting period before attempting to conceive. The FSRH, the Royal College of Obstetricians and Gynaecologists (RCOG), and the British Obesity and Metabolic Surgery Society (BOMSS) advise that women should avoid pregnancy for at least 12–18 months following bariatric surgery, or until weight has stabilised. This recommendation reflects the significant nutritional and metabolic changes that occur during the rapid weight loss phase.

In the months immediately following surgery, the body undergoes substantial changes, including:

• Rapid weight loss, which can affect foetal development if conception occurs during this period

• Nutritional deficiencies, particularly in iron, folate, vitamin B12, vitamin D, and calcium — all of which are critical for a healthy pregnancy

• Hormonal fluctuations as fat stores decrease and oestrogen levels shift

Pregnancy conceived during this period carries an increased risk of intrauterine growth restriction, preterm birth, and micronutrient deficiency-related complications. Paradoxically, fertility often improves significantly after bariatric surgery, particularly in women with polycystic ovary syndrome (PCOS) or obesity-related anovulation, making effective contraception even more important in the post-operative period.

If pregnancy occurs sooner than recommended, women should seek early referral to specialist obstetric care with bariatric input, as additional monitoring and nutritional support will be required.

Women who wish to conceive after the recommended waiting period should undergo pre-conception counselling with their GP or bariatric team, including a full nutritional assessment. Typical pre-conception checks include iron, folate, vitamin B12, vitamin D, and calcium levels, alongside any other tests recommended by the bariatric team. Folic acid supplementation should be commenced at least three months before attempting conception:

• 400 micrograms daily for most women

• 5 mg daily for women with a BMI of 30 kg/m² or above, diabetes, or those taking certain medications (e.g., anti-epileptic drugs) — as advised by NICE CKS pre-conception guidance

Women should discuss their full supplement regimen with their GP or bariatric team before and during pregnancy.

Talking to Your GP or Bariatric Team About Contraceptive Choices

Contraceptive planning should ideally begin before surgery; patients should discuss current methods, pregnancy intentions, VTE history, and UKMEC-assessed risk factors with their GP or bariatric team to identify the most suitable option.

Navigating contraceptive choices after gastric sleeve surgery can feel complex, but open communication with your healthcare team is the most important step. Ideally, contraceptive planning should begin before surgery, as part of the pre-operative assessment process. Many bariatric programmes in the UK include a discussion of contraception as standard, but if this has not been addressed, patients should proactively raise it with their GP or bariatric nurse.

When attending an appointment, it is helpful to discuss:

• Your current contraceptive method and whether it remains appropriate post-surgery, including any perioperative changes needed (e.g., stopping CHC before major surgery)

• Your future pregnancy intentions, including timing and any fertility concerns

• Any relevant medical history, such as a history of VTE, migraine with aura, hormone-sensitive conditions, or osteoporosis risk, which may influence which methods are safe for you — your clinician will use the UKMEC framework to guide this

• Non-oral CHC options (patch or vaginal ring) if you prefer combined hormonal contraception but wish to avoid oral tablets

• Nutritional status and supplementation, particularly if considering pregnancy in the future

Your GP can refer you to a sexual health clinic or community contraceptive service for LARC fitting, or provide a prescription for injectable contraception. If you experience any unexpected bleeding, contraceptive failure, or symptoms that concern you — such as signs of pregnancy or VTE (leg pain, swelling, breathlessness) — contact your GP promptly or attend an urgent care service.

For urgent access to emergency contraception, contact a sexual health clinic, pharmacy, GP surgery, or call NHS 111. Use the NHS sexual health clinic finder at nhs.uk/service-search/sexual-health to locate your nearest service.

If you experience a suspected side effect from any contraceptive medicine or device, please report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

There is no single 'best' contraceptive method for every gastric sleeve patient, as individual health factors, lifestyle, and reproductive goals all play a role. The consistent clinical consensus in the UK — supported by NICE NG216, FSRH guidance, UKMEC, RCOG, and BOMSS — is that LARC methods are the most reliable and appropriate first-line options for most women following bariatric surgery, while oral methods remain generally acceptable after restrictive procedures for those without other contraindications. A personalised, informed discussion with your healthcare team will ensure you receive the most suitable and evidence-based advice for your circumstances.

Frequently Asked Questions